Here is a list of DPP-4 inhibitors, their FDA-approved usage / indications, and the side effects that we are currently investigating:
Onglyza / Kombiglyze / Nesina / Kazano / Oseni / Glyxambi / Janumet / Januvia / Jentadueto / Tradjenta
Prescribed/Used for:
Treatment of type 2 diabetes mellitus (improve glycemic control):
-Onglyza
-Kombiglyze XR (when treatment with both saxagliptin and metformin is appropriate)
-Nesina
-Kazano (when treatment with both alogliptin and metformin is appropriate)
-Oseni (when treatment with both alogliptin and pioglitazone is appropriate)
-Glyxambi (when treatment with both empagliflozin and linagliptin is appropriate)
-Janumet (when treatment with both sitagliptin and metformin is appropriate)
-Januvia
-Jentadueto (when treatment with both linagliptin and metformin is appropriate)
-Tradjenta
Side Effects We Are Investigating:
– Heart Failure
– Renal Failure / Kidney Failure
– Kidney Problems
– Decreased Renal Function
– Myocardial Infarction (MI) / Heart Attacks
– Cerebral Infarction / Cerebrovascular Accident (CVA) / Strokes
– Unexpected Death
– Acute Pancreatitis
– Inflammatory Bowel Disease (IBD)
– Severe Joint Pain
Recent articles by attorney Tom Lamb on the Drug Injury Law web site:
-
- Diabetes Drugs In DPP-4 Inhibitor Class Significantly Increase Risk Of Crohn’s Disease (CD)
- Certain Diabetes Drugs Like Januvia Associated With Bile Duct Cancer
- Certain Diabetes Drugs Side Effects Include Heart Attacks And Strokes
- DPP-4 Inhibitor Diabetes Drugs Linked To Inflammatory Bowel Disease
- Current Number Of Lawsuits Filed In The Four Diabetes Drugs Federal Court MDL Cases
Go to Drug Injury or Death Case Evaluation for Onglyza / Kombiglyze / Nesina / Kazano / Oseni / Glyxambi / Janumet / Januvia / Jentadueto / Tradjenta